March crystallised a new market rule: AI that cannot show auditability, clinician override and standards-level connectivity will not win major Australian contracts. ADHA's National Clinical Governance Centre for Digital Health arrived as vendors were already fielding HL7 scribe pilots from Faz and MedLuma, Healthdirect's relaunch as 1800Medicare introduced AI triage at scale, and AU eRequesting pushed a national FHIR diagnostic standard. Buyers now price governance and integration as table stakes.

AI integration

Scribes, front-door agents and clinical assistants moved from trials into everyday use. Faz's MedTalk pilot inside Epic, ChatGPT Health style agents and Buddy AI in community care (1,000 workers) showed real productivity gains. The consequence is clear. Large EMR and enterprise vendors that can ship HL7 or FHIR connectors, audit logs and local governance controls gain leverage. Small point-solution suppliers face a choice: embed with platform partners or be squeezed out of public and large private tenders.

Buyers and governance

ADHA's new governance centre rewrites procurement checklists. Demonstrable data lineage, routine performance monitoring and clinician override are now procurement filters not optional features. That slows some rollouts in the near term but reduces regulatory exposure for buyers. Vendors that already surface evidence and monitoring will win faster access to public contracts. Teams that have not budgeted for product-level controls must reprioritise roadmaps now.

Platform interoperability

Platform moves tightened network effects. Telstra Health's Smart Connect linking MedicalDirector to Healius pathology via FHIR, Gold Coast Health's Miya Precision remote monitoring and Five Faces' integrated patient journey tools made end-to-end workflows operative. AU eRequesting Release 1.0 means faster diagnostic cycles for systems that implement it. In practice, integrated EMRs and lab networks will capture routine work while standalone vendors become exception handlers.

Capacity constraint

Clinical volume and supply pressures made the month actionable. Drug approvals and PBS changes for Alzheimer therapies, pembrolizumab expansions and tightly managed GLP-1 pathways increase MRI, oncology and monitoring demand. HeartSight cut echo read time by more than 80 percent, but MRI access and genomics capacity lag. New Zealand's Illumina onshore pilot for 6,000 samples underlines Australia’s gap. Equity risks rose as Beamtree warned genomic programmes could exclude First Nations people unless data platforms and community governance improve.